Linden Thomas Advisory Services’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Linden Thomas Advisory Services’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.5M	Sell	54,803 -66,974	-55%	-$3.47M	0.28%	90
2026 Q1	$5.86M	Buy	121,777 +7,315	+6%	+$324K	0.57%	22
2025 Q4	$4.72M	Sell	114,462 -1,578	-1%	-$63.3K	0.48%	48
2025 Q3	$4.51M	Sell	116,040 -75	-0.1%	-$2.44K	0.46%	51
2025 Q2	$3.21M	Sell	116,115 -1,166	-1%	-$29.7K	0.35%	74
2025 Q1	$2.6M	Sell	117,281 -323	-0.3%	-$6.65K	0.34%	80
2024 Q4	$2.33M	Sell	117,604 -106	-0.1%	-$2.42K	0.29%	99
2024 Q3	$2.94M	Sell	117,710 -592	-0.5%	-$14.4K	0.4%	55
2024 Q2	$2.21M	Buy	118,302 +1,921	+2%	+$36K	0.34%	72
2024 Q1	$2.3M	Buy	116,381 +1,831	+2%	+$35.8K	0.37%	61
2023 Q4	$2.01M	Sell	114,550 -1,341	-1%	-$22K	0.38%	66
2023 Q3	$2.01M	Buy	115,891 +57,942	+100%	+$976K	0.45%	45
2023 Q2	$816K	Buy	+57,949	New	+$776K	0.18%	230

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Linden Thomas Advisory Services's KNSA Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Kiniksa Pharmaceuticals (KNSA) stake by 55% in Q2 2026, selling an estimated $3.47M and leaving 54,803 shares worth $3.5M. The position accounts for 0.28% of the portfolio, ranked #90.

Linden Thomas Advisory Services first reported a position in KNSA in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.86M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Linden Thomas Advisory Services held 54,803 shares of Kiniksa Pharmaceuticals worth $3.5M as of Q2 2026.
Linden Thomas Advisory Services sold 66,974 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.47M.
Kiniksa Pharmaceuticals made up 0.28% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #90 holding.
Linden Thomas Advisory Services first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Linden Thomas Advisory Services's Kiniksa Pharmaceuticals position peaked at $5.86M in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.